NCT03499691CompletedNot Applicable
An Open-label, Prospective, Randomized, Parallel-Group, Exploratory Study to Explore the Safety and Efficacy of the HDx Therapy Using Theranova 500 Dialyzer in Comparison to Hemodiafiltration
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Vantive Health LLC
- Enrollment
- 43
- Locations
- 1
- Primary Endpoint
- Reduction ratios of fibroblast growth factor 23 (FGF-23)
Study Overview
Brief Summary
Today it is well established that middle molecules comprise several compounds that are not effectively removed by high-flux dialyzers, and effective clearance of large middle molecules in the process of dialysis depends on the dialyzer membrane having large enough pore sizes, larger than the conventional high-flux dialyzers. Studies have found associations between levels of large middle molecule uremic toxins and immune dysfunction and inflammation, as well as adverse outcomes. This indicates that dialysis membranes having larger pores, enabling an expanded HD (HDx) with more effective removal of large middle molecules, can have a positive impact on the inflammatory state. While data is starting to appear on the long-term use of the HDx therapy, little is still known on how large middle molecules and inflammation markers are affected over time.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •ESRD patients age between 18 - 80 years
- •Clinically stable as judged by the treating physician for 30 days prior to enrollment, as demonstrated by pertinent patient medical history, physical examination, and laboratory testing
- •Hemodialysis therapy with HDF for at least 3 months immediately prior to study enrollment
Exclusion Criteria
- •No informed consent provided
- •Significant psychiatric disorder, mental disability, or other condition that may interfere with the patient's ability to provide informed consent
- •Pregnant, breastfeeding, or planning to become pregnant
- •Unstable vascular access associated with risk of low and variable extracorporeal blood flow rate (QB)
- •Chronic liver disease, known paraprotein-associated disease, known bleeding disorders (e.g., gastrointestinal bleed, colonic polyps, small bowel angiodysplasia and active peptic ulcers)
- •Major bleeding episode (i.e. soft tissue bleeding, blood in stool, joint damage, retinal bleeding, extensive mucosal bleeding, exsanguination, cerebral hemorrhage) ≤ 12 weeks prior to enrollment
- •Blood (red blood cell) transfusion ≤ 12 weeks prior to enrollment
- •Clinical signs of acute infection ≤ 4 weeks prior to enrollment
- •Active cancer, except for basal cell or squamous cell skin cancer
- •Positive serology test for human immunodeficiency virus or hepatitis infection
- •Scheduled for planned interventions requiring hospitalization > 1 week
- •Scheduled for living-donor transplantation within the study period
- •Currently participating in another interventional clinical study or has participated in another interventional clinical study in the past 3 months that may interfere with this study
Outcomes
Primary Outcomes
Reduction ratios of fibroblast growth factor 23 (FGF-23)
Time Frame: Week 12
Reduction ratios of lambda immunoglobulin free light chains (λ-FLC)
Time Frame: Week 12
Reduction ratios of chitinase-3-like protein 1 (YKL-40)
Time Frame: Week 12
Reduction ratios of kappa immunoglobulin free light chains (k-FLC)
Time Frame: Week 12
Reduction ratios of serum beta-2 microglobulin (β2M)
Time Frame: Week 12
Secondary Outcomes
- Percent change from pre- to post-dialysis in mid-week serum levels of IL-6(Week 12)
- Change from baseline in mid-week pre-dialysis serum levels of λ-FLC, κ-FLC, YKL-40, FGF-23, ß2M(Week 12 and 24)
- Transferrin Saturation (TSAT)(Baseline, Week 12, Week 24)
- 24-hour urine output on monthly basis(Month 1, Month 2, Month 3, Month 4, Month 5, Month 6)
- Erythropoiesis stimulating agent (ESA) responsiveness(Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24)
- Total patient death(Week 1 through Week 24)
- Change from baseline in mid-week pre-dialysis serum level of fibrinogen(Week 12 and 24)
- ESA dosage by type, administration frequency, and route(Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24)
- Change from baseline in mid-week pre-dialysis serum levels of pentraxin-3 (PTX-3), high sensitivity C-reactive protein (hs-CRP), interleukin (IL-6), and interleukin-10 (IL-10)(Week 12 and 24)
- Percent change from pre- to post-dialysis in mid-week serum levels of PTX-3(Week 12)
- Percent change from pre- to post-dialysis in mid-week serum levels of IL-10(Week 12)
- Change from baseline in mid-week pre-dialysis serum level of albumin(Week 12 and 24)
- Serum phosphorous(Week 24)
- Dialysis Symptom Index (DSI)(Baseline, Week 12, Week 24)
- Number of adverse events of hospitalization, cardiovascular events, and infective episodes(Week 1 through Week 24)
- Intravenous iron dosage(Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24)
- Percent change from pre- to post-dialysis in mid-week serum levels of hs-CRP(Week 12)
- Single pool Kt/Vurea(Week 24)
- Kidney Disease Quality of Life 36 (KDQOL-36)(Baseline, Week 12, Week 24)
- Serum ferritin(Baseline, Week 12, Week 24)
- Hemoglobin levels(Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 4
A randomized, open-label, positive drug parallel controlled clinical trial of Kesuting syrup in the treatment of COVID-19 (Light)COVID-19ITMCTR2200005986Shanghai Public Health Clinical Center
Recruiting
Phase 4
â??multicentric, open-label, safety and efficacy study of Fibroheal® (CentellaAsiatica herbal wound healing sheet) in split- thickness skin graft donor sitetreatment and partial thickness wounds caused by Trauma/burns.CTRI/2014/07/004732SericareDivision of Healthline Pvt Ltd Funded by SIBRI DBT12
Not yet recruiting
Phase 2
opinavir/r/ Lamivudine/ Abacavir as an Easy to Use Paediatric Formulation (LOLIPOP)PACTR201903696308665Drugs for Neglected Diseases initiative45
Completed
Phase 2
An open, non-randomized, parallel-group pharmokinetic and -dynamic, investigator-initiated study on effects of obeticholic acid (OCA) in bile of patients with primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) in comparison to healthy controlsPrimary biliary cholangitissmall bile duct injury10019654fatty liver diseasenon-alcoholic steatohepatitisNL-OMON47216Academisch Medisch Centrum33
Active, not recruiting
Phase 1
A study on the effect of obetihcolic acid on bile composition in patients with PBC (chronic liver disease of the small bile ducts), NASH (chronic liver disease as a result of fatty liver) and healthy volunteersPrimary biliairy cholangitis (PBC)Non-alcoholic steatohepatitis (NASH)MedDRA version: 20.0Level: SOCClassification code 10019805Term: Hepatobiliary disordersSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2016-002965-67-NLAMC